The Food and Drug Administration's (FDA) new expedited drug program, championed by Commissioner Marty Makary, has sparked a wave of anxiety and confusion among agency staff. This program, which promises approval in as little as one month for medicines supporting "U.S. national interests," has raised significant legal and ethical concerns. The program's lack of formal rules and regulations has led to questions about the legal authority of officials to sign off on drugs cleared under it.
The program's rapid review process, which bypasses traditional review scientists and their immediate supervisors, has caused alarm. Drug reviewers report receiving little information about the program's workings, and some staff were recently told they could skip certain regulatory steps to meet aggressive deadlines.
Despite the program's popularity at the White House, where pricing concessions have been accompanied by FDA vouchers for drugmakers, there are concerns about its sustainability. The program's lack of codification means it could be wiped out by the next administration, and its rapid review process may not be legally sound.
The program has also been criticized for its potential to politicize drug reviews, which have traditionally been pegged to objective standards and procedures. The involvement of senior agency leaders, led by Dr. Vinay Prasad, in the approval process has raised questions about the program's transparency and susceptibility to political influence.
Furthermore, the program's rapid review process has led to concerns about the safety and effectiveness of drugs. The recent delay in the review of two drugs in the program, due to safety concerns, including the death of a patient taking one of the medications, highlights the risks associated with expedited reviews.
In conclusion, the FDA's new expedited drug program has raised significant legal, ethical, and scientific concerns. Its rapid review process, lack of formal rules, and potential for politicization have sparked a wave of anxiety and confusion among agency staff. The program's sustainability and the safety and effectiveness of drugs cleared under it remain in question.
